A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older
Latest Information Update: 27 Apr 2023
Price :
$35 *
At a glance
- Drugs V 01 Livzon Mabpharm/Institute of Biophysics, Chinese Academy of Sciences (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Livzon Pharmaceuticals
- 22 Apr 2023 Planned End Date changed from 22 Apr 2023 to 14 Jun 2023.
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT05096845).